Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

How ValiRx (LSE:VAL) Narrowed Its Half-Year Loss Under a Leaner Cancer Drug Development Strategy

ValiRx is an AIM-quoted life sciences company developing early-stage cancer therapeutics and women's health treatments. Rather than running largeClinical Trialsitself, it works through subsidiaries and partnerships. Cytolytix, a majority-owned subsidiary, is developing CLX001, a nanoparticle immunotherapy. Inaphaea BioLabs operates a biobank of patient-derived cells …

Divya Sood | 05 October 2026

Why 4basebio (LSE:4BB) Reported Lower Half-Year Revenue as Its Synthetic DNA Pipeline Expanded

4basebio (LSE:4BB) is an AIM-quoted biotechnology company that produces synthetic DNA for genetic medicines. Its proprietary opDNA product is made enzymatically rather than through traditional bacterial fermentation, and is used as starting material for mRNA vaccines and therapies, cell therapies and viral vectors. The …

Divya Sood | 05 October 2026

Why Is MedPal AI plc (LSE:MPAL) Down 7.87% Today and What Are Investors Watching?

• MedPal AI plc (LSE:MPAL) is down 7.87% in the 5 October 2026 move shown, placing it among the notable decliners in the session.

Ankur Sharma | 05 October 2026

How Hikma Pharmaceuticals (LSE:HIK) Plans to Raise R&D Spending to Deepen Its Medicines Pipeline

Hikma develops, manufactures and sells generic, specialty and branded medicines. Its half-year report divides the business into three segments: Injectables, which supplies hospital products; Hikma Rx, its US retail generics arm; and Branded, which sells mainly in the Middle East and North Africa. The …

Ankur Sharma | 05 October 2026

Why EDX Medical Group (LSE:EDX) Raised £2.7m to Expand Its Employee Health Screening Service

EDX Medical describes itself as a developer of "innovative digital diagnostic products and services" focused on early disease detection and treatment. According to its annual report, it runs laboratory facilities in Cambridge and works across hereditary and genetic risk assessment, early disease detection and …

Ankur Sharma | 05 October 2026

How Cambridge Cognition (LSE:COG) Joined C2N and The Alzheimer's Trust in a UK Dementia Diagnostic Pathway

Cambridge Cognition develops "digital cognitive assessments" used in clinical studies,Drug Developmentand patient care. Its main platforms are CANTAB, a set of computerised cognitive tests, and Winterlight, which analyses speech to assess cognition. Pharmaceutical companies use its tools to measure cognitive effects in trials, while …

Ankur Sharma | 05 October 2026

How Genus (LSE:GNS) Cut Its Net Debt After Forming the PIC China Joint Venture

Genus is a London-listed company headquartered in Basingstoke. It supplies breeding animals and genetic material to livestock producers in more than 24 countries. Its porcine division, Genus PIC, earnsRevenuefrom breeding stock and royalties linked to the genetic improvement it delivers to pork producers. Its …

Ankur Sharma | 05 October 2026

How PureTech Health (LSE:PRTC) Swung to a Half-Year Profit on Its Seaport Therapeutics Stake

PureTech (LSE:PRTC) is listed on the London Stock Exchange's Main Market. It describes itself as "a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value". In practice, it develops therapeutic candidates internally and then places them in separately funded …

Ankur Sharma | 05 October 2026

How Proteome Sciences (LSE:PRM) Narrowed Its Half-Year Loss as TMT Reagent Income Grew

Proteome Sciences is an AIM-quoted life sciences company specialising in proteomics, the large-scale analysis of proteins. It earns money in two ways. Its laboratories in Frankfurt, which hold GCLP accreditation for work supporting clinical trials, and San Diego provide mass spectrometry-based protein analysis services …

Ankur Sharma | 05 October 2026

Why Is HemoGenyx Pharmaceuticals PLC (LSE:HEMO) Stock Up 9.20% and What Is the Clinical Catalyst?

• The strongest recent catalyst is the company’s September 2026 interim update, which highlighted encouraging observations in three adult patients treated at the first dose level of its HG-CT-1 CAR-T programme. The company said the trial was positioned for dose escalation, whileManufacturingfor HG-CT-1 had …

Ankur Sharma | 05 October 2026
Support

Hi! How can we help you today?

Loading…